Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 1/2008

01-03-2008

Genetic counseling and clinical management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations: perspective of a surgical oncologist

Author: Edibaldo Silva

Published in: Familial Cancer | Issue 1/2008

Login to get access

Abstract

Women with a family history of breast cancer who are diagnosed with breast cancer are often counseled to undergo prophylactic mastectomy as part of their treatment for breast cancer. The majority of such individuals make these decisions in haste and without appropriate genetic counseling or testing. Most of them when tested for BRCA or other established mutations find that they are not mutation carriers. In retrospect, this realization leads many to question the wisdom of their prophylactic surgery which is often associated with complications and quality of life problems which they never envisioned. We have designed an algorithm for the management of these patients which minimizes these lifelong problems.
Literature
1.
Stolier A, Fuhrman G et al (2004) Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA1 or BRCA2 mutation. Breast J 10:475–480PubMedCrossRef
2.
Ganguly A, Leahy K et al (1997) Genetic testing for breast cancer susceptibility: frequency of BRCA1 and BRCA2 mutations. Genet Test 2:85–90
3.
Lakhani SR, van de Vijver MJ et al (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers, estrogen receptor, progesterone receptor, HER-2 Neu and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310–2318PubMedCrossRef
4.
Foulkes WD, Metcalfe K et al (2003) Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer 98:1569–1577PubMedCrossRef
5.
Brekelmans CTM, Seynaeve C et al (2001) Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 19:924–930PubMed
6.
Scheuer L, Kauf N et al (2002) Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20:1260–1268PubMedCrossRef
7.
Schwartz G, Hortogyi GN (2004) Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of breast, April 26–28, 2003, Philadelphia, Pennsylvania. Cancer 100:2512–2532PubMedCrossRef
8.
Wolmark N, Wang J, Mamounas E et al (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from NSABP B-18. J Natl Cancer Inst Monogr 30:96–102PubMed
9.
Cady B, Chung M et al (2006) Re: genetic counseling and management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations. Breast J 12:282–283CrossRef
10.
Mammounas EP, Fisher B (2001) Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Semin Oncol 28:389–399CrossRef
11.
Tsikitis V, Chung M et al (2004) Scientific basis of neoadjuvant therapy. Semin Breast Dis 7:51–57CrossRef
12.
Warner E, Trudeau M et al (2003) Sensitivity of BRCA1-related breast cancer to neoadjuvant chemotherapy. Practical implications. Breast J 9:507–508
13.
Pierce LJ, Struderman M et al (2000) Effect of radiotherapy after breast conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 18:3360–3369PubMed
14.
Hafty B, Harrold E et al (2002) Outcome of conservatively managed early onset breast cancer by BRCA1/2 status. Lancet 359:1471–1477CrossRef
15.
Komenaka IK, Ditkoff BA et al (2004) The development of interval breast malignancies in patients with BRCA mutations. Cancer 100:2079–2083PubMedCrossRef
16.
Ascherman JA, Hanasono MM et al (2006) Implant reconstruction in breast cancer patients treated with radiation therapy. Plast Reconstr Surg 117:359–365PubMedCrossRef
17.
Narod SA, Offit K (2005) Prevention and management of hereditary breast cancer. J Clin Oncol 23:1656–1663PubMedCrossRef
18.
Hartmann LC, Schaid DJ (1999) Effect of bilateral prophylactic mastectomy in women with a familial history of breast cancer. N Engl J Med 340:77–84PubMedCrossRef
19.
Hartmann LC, Sellers TA et al (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93:1633–1637PubMedCrossRef
20.
Schwartz M (2005) Contralateral prophylactic mastectomy: efficacy, satisfaction, regret. J Clin Oncol 23:7777–7779PubMedCrossRef
21.
Rebbeck TR, Friebel T et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers. The PROSE Study Group. J Clin Oncol 221:1055–1062CrossRef
22.
Meijers-Heijboer H, van Geel B et al (2001) Breast cancer after prophylactic bilateral mastectomy in women with BRCA1 or BRCA2 mutations. N Engl J Med 345:159–164PubMedCrossRef
23.
Walsh T, Casadei S et al (2006) Spectrum of mutations in BRCA1, BRCA2, chek2, and TP53 in families at high risk of breast cancer. JAMA 295:1379–1387PubMedCrossRef
24.
Eisen A, Rebbeck TR et al (2000) Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol 18:1980–1995PubMed
25.
Rebbeck TR, Lynch HT et al (2002) Prophylactic oophorectomy in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 346:1616–1621PubMedCrossRef
26.
Watson P, Narod SA et al (2003) Carrier risk status changes resulting form mutation testing in hereditary non-polyposis colorectal cancer and hereditary breast ovarian cancer. J Med Genet 40:591–596PubMedCrossRef
Metadata
Title
Genetic counseling and clinical management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations: perspective of a surgical oncologist
Author
Edibaldo Silva
Publication date
01-03-2008
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2008
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-007-9167-3

Other articles of this Issue 1/2008

Familial Cancer 1/2008 Go to the issue

OriginalPaper

Hereditary diffuse gastric cancer: association with lobular breast cancer

OriginalPaper

Roles and responsibilities of a medical geneticist

OriginalPaper

Pancreatic cancer and the FAMMM syndrome

OriginalPaper

Pathology of the hereditary colorectal carcinoma

OriginalPaper

Chemoprevention with special reference to inherited colorectal cancer

OriginalPaper

Standards of care in diagnosis and testing for hereditary colon cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits